Why Intersect ENT is an Example of Hope for the Medtech Industry
- Author
- Scott Nelson
- Published
- Fri 26 Apr 2013
- Episode Link
- https://share.transistor.fm/s/bff72a32
The 2.3% medical device tax is burdensome. Regulatory timelines are long (and expensive). Reimbursement is not only decreasing, but also incredibly hard to obtain. Venture capitalists are losing interest in early stage medical device deals. Is it all downhill for medtech? There is no doubt the current healthcare environment is challenging. But certainly not impossible...[read more]
Related Articles
